Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients

Table 2 Visual/anatomic outcomes between ‘persistent SRF (+) group’ and ‘persistent SRF (-) group’ in type 1 CNV and type 2 CNV

Characteristics.	Type 1 CNV		p	Type 2 CNV		p
Characteristics.	Persistent SRF (+) group (n = 44)	Persistent SRF (−) group (n = 33)	p	Persistent SRF (+) group (n = 18)	Persistent SRF (−) group (n = 35)	p
No. of intravitreal anti-VEGF injections (mean ± SD)
1 year	7.2 ± 1.5	6.7 ± 1.7	0.175	7.3 ± 1.4	6.5 ± 1.4	0.059
2 year	5.4 ± 1.7	4.7 ± 2.0	0.092	5.4 ± 1.8	4.9 ± 1.1	0.276
Total	12.6 ± 2.7	11.3 ± 3.3	0.073	12.7 ± 2.7	11.4 ± 2.1	0.061
Values at baseline (mean ± SD)
BCVA, logMAR	0.52 ± 0.27	0.58 ± 0.35	0.453	0.70 ± 0.30	0.78 ± 0.39	0.443
CST, μm	386.95 ± 119.15	412.88 ± 128.44	0.364	446.11 ± 121.83	431.91 ± 137.02	0.713
SFCT, μm	305.03 ± 78.74	276.78 ± 72.40	0.142	264.31 ± 76.03	211.26 ± 71.79	0.023
Values at 2 years after anti-VEGF injections (mean ± SD)
BCVA, logMAR	0.35 ± 0.25	0.35 ± 0.26	0.900	0.42 ± 0.28	0.55 ± 0.35	0.192
CST, μm	303.02 ± 57.34	275.45 ± 67.67	0.057	314.28 ± 67.56	269.11 ± 53.84	0.011
SFCT, μm	294.14 ± 77.97	262.64 ± 73.66	0.077	249.94 ± 77.36	200.46 ± 75.45	0.029
ELM intact/defect	41/3	29/4	0.423	14/4	19/16	0.095
EZ intact/defect	23/21	19/14	0.644	8/10	8/27	0.105
COST line intact/defect	1/43	2/31	0.395	1/17	0/35	0.159
Δ PRL thickness from After 3rd injection	−5.70 ± 2.66	−6.58 ± 2.45	0.145	−6.22 ± 3.72	−8.40 ± 3.84	0.054

CNV choroidal neovascularization, SRF subretinal fluid, VEGF vascular endothelial growth factor, SD standard deviation, BCVA best-corrected visual acuity, logMAR logarithm of the minimal angle of resolution, CST central subfield thickness, SFCT subfoveal choroidal thickness, ELM external limiting membrane, EZ ellipsoid zone, COST con outer segment tip, PRL photoreceptor layer

ISSN: 1471-2415